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ABSTRACT 
CONTEXT AND OBJECTIVE: One third of all cervical carcinomas occur during the reproductive period. Cervical carcinoma is the second greatest cause of 
death due to cancer during this phase. The estimated frequency of cervical cancer during pregnancy is one case for every 1,000 to 5,000 pregnancies. 
The aim here was to provide information about the difficulties in diagnosing and managing cervical neoplasia during pregnancy. 
MATERIALS: A systematic review of the literature was undertaken through the PubMed, Cochrane, Excerpta Medica (Embase), Literatura Latino Americana 
e do Caribe em Ciências da Saúde (Lilacs) and Scientific Electronic Library Online (SciELO) databases, using the following words: pregnancy, cervical 
cancer, diagnosis and management. 
RESULTS: There was a consensus in the literature regarding diagnosis of cervical carcinoma and management of preneoplastic lesions during pregnancy. 
However, for management of invasive carcinoma, there was great divergence regarding the gestational age taken as the limit for observation rather than 
immediate treatment. 
CONCLUSION: All patients with cytological abnormalities should undergo colposcopy, which will indicate and guide biopsy. Conization is reserved for 
patients with suspected invasion. High-grade lesions should be monitored during pregnancy and reevaluated after delivery. In cases of invasive carcinoma 
detected up to the 12th week of pregnancy, patient treatment is prioritized. Regarding diagnoses made during the second trimester, fetal pulmonary 
maturity can be awaited, and the use of chemotherapy to stabilize the disease until the time of delivery appears to be viable. 
RESUMO
CONTEXTO E OBJETIVO: Um terço dos carcinomas de colo ocorrem no período reprodutivo, sendo que esta é a segunda causa de morte por câncer nessa 
fase. A freqüência estimada do carcinoma de colo uterino na gravidez é de um caso para cada 1.000 a 5.000 gestações. O objetivo foi informar sobre 
as dificuldades frente ao diagnóstico e manejo da neoplasia cervical durante a gravidez. 
MATERIAIS E MÉTODOS: Revisão sistemática da literatura foi realizada no PubMed, Cochrane, Excerpta Medica (Embase), Literatura Latino Americana 
e do Caribe em Ciências da Saúde (Lilacs) and Scientific Electronic Library Online (SciELO), usando as seguintes palavras: gestação, câncer cervical, 
diagnóstico e manejo. 
RESULTADOS: A literatura apresenta consenso quanto ao diagnóstico do carcinoma cervical e a conduta das lesões pré-neoplásicas durante a gestação. 
No manejo do carcinoma invasor há grande divergência quanto à idade gestacional considerada como limite para a adoção da observação em vez do 
tratamento imediato.
CONCLUSÃO: Toda paciente com citologia alterada deve realizar colposcopia, a qual indicará e a biópsia. A conização é reservada para pacientes com 
suspeita de invasão. As lesões de alto grau devem ser acompanhadas durante a gestação e reavaliadas após o parto. Em casos de carcinoma invasor em 
gestantes com até 12 semanas o tratamento da paciente é priorizado. Nos diagnósticos ocorridos no segundo trimestre, pode-se aguardar a maturidade 
pulmonar fetal e o uso da quimioterapia para estabilizar a doença até o momento do parto parece ser viável. 
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INTRODUCTION
One third of all cervical carcinomas occur during the reproductive 
period.1,2 This type of neoplasia is the second greatest cause of death due 
to cancer, only preceded by breast cancer of the breast. It is followed in 
frequency by lymphomas, melanoma and thyroid carcinoma.3,4
About 3% of cases of cervical cancer are diagnosed during 
pregnancy,5 and these cases correspond to half of the cases of neoplasia 
diagnosed during the gestational period. Cervical cancer is the most fre-
quently found malignancy worldwide. The estimated frequency is one 
case per 1,000 to 5,000 pregnancies.5,6
Current evidence indicates that the chance that pregnant women 
will be diagnosed with cervical cancer while it is in its initial stages is 
three times greater than the chance among controls. This is due to in-
spections and cervical cytological tests conducted among women in 
countries where these examinations are part of routine prenatal care. 
Several studies have shown that 76% of the lesions diagnosed during 
pregnancy are in stage IB4-11 (Table 1).
Although diagnoses of cervical cancer during pregnancy are usually 
made while the disease stage is operable, this time does not always coincide 
with fetal maturity, thus causing anguish for both the patient and the medi-
cal team. The aim of the present paper was to provide information about the 
difficulties in diagnosing and managing cervical cancer during pregnancy.
Table 1. Comparison of staging at the time of diagnosing cervical cancer 
in pregnant and non-pregnant women9,56
Staging Pregnant Non-pregnant
Stage I 70-80% 42%
Stage II 11-20% 35%
Stage III 3-8% 21%
Stage IV 0-3% 2%
Table 2. Systematic review of the literature, searching for papers published 
over the last 13 years (1996-2009)
Database Strategy of search Results
PubMed Pregnancy [MeSH] AND cervical 
cancer [MeSH] AND diagnosis 
[MeSH] AND management  
[MeSH] 
324 articles
91 review articles
86 management articles
64 screening articles
29 cross-sectional prevalence 
studies
25 guidelines
15 clinical trials
14 case histories
Cochrane Pregnancy [MeSH] AND cervical 
cancer [MeSH] AND diagnosis 
[MeSH] AND management 
[MeSH]
41 articles
37 systematic reviews
2 clinical trials
2 economic evaluations 
Embase (Excerpta 
Medica Database)
Pregnancy [MeSH] AND cervical 
cancer [MeSH ] AND diagnosis 
[MeSH] AND management 
[MeSH]
20 articles
10 guidelines
5 systematic reviews 
3 cross-sectional prevalence 
studies
2 clinical trials
Lilacs (Literatura 
Latino-Americana e 
do Caribe em Ciên-
cias da Saúde)
Gestação [DeCS] AND câncer 
cervical [DeCS] AND diagnós-
tico [DeCS] AND tratamento
2 articles
1 case history
1 systematic reviews
SciELO (Scientific 
Electronic Library 
Online)
Gestação [DeCS] AND câncer 
cervical [DeCS] AND diagnós-
tico [DeCS] AND tratamento
11 articles
9 case histories
2 systematic reviews
MeSH = Medical Subjects Headings; DeCS = Descritores em Ciências da Saúde.
MATERIALS
The present review discusses the current guidelines for diagnosis and 
management of cervical cancer associated with pregnancy. A systemat-
ic review of the literature was undertaken by searching in the PubMed, 
Cochrane, Excerpta Medica (Embase), Literatura Latino Americana e 
do Caribe em Ciências da Saúde (Lilacs) and Scientific Electronic Li-
brary Online (SciELO) databases. The study was developed using the 
following key words: pregnancy, cervical cancer, diagnosis and manage-
ment. The search strategies and the results are shown in Table 2. Arti-
cles published since 1996 were selected according to the following cri-
teria: literature reviews, prospective studies and case reports presenting 
approaches for diagnosing and managing cancer of the uterine cervix 
during pregnancy, particularly using innovative treatments, protocols 
and consensuses from institutions specializing in this disease. Articles 
reporting on diagnosis and management of cervical cancer among non-
pregnant women and articles that evaluated the prognosis for a future 
pregnancy when comparing the various types of treatment for this dis-
ease were excluded from this review.
DIAGNOSIS
The diagnosis of cervical carcinoma in pregnant women is based on 
clinical findings, inspection of the uterine cervix, cytological tests, col-
poscopy, directed biopsy and imaging examinations.9
Clinical findings
In most cases, patients with stage I cervical carcinoma are asymp-
tomatic at the time of diagnosis. When symptomatic, they report yel-
lowish, fetid or bloody vaginal content, postcoital bleeding and vague 
pain in the hypogastrium. At more advanced stages, patients may report 
lumbar pain, hematuria, changes in micturition and changes in intesti-
nal habitus.5,9 The most prevalent symptom during pregnancy is vaginal 
bleeding, which is present in 50% of the cases.10
Inspection of the uterine cervix
The uterine cervix undergoes general modification during pregnan-
cy due to the physiological and hormonal changes that occur during 
this period. The cervix may double or almost triple in size by the end of 
pregnancy and the transformation zone becomes exuberant due to ever-
sion of the squamocolumnar junction, thus enabling better viewing. 
These changes may be confused with neoplastic lesions.5,12
Cytology
There is no difference in the incidence of neoplastic cytopatholog-
ical changes between pregnant and non-pregnant women, and these 
changes may reach 8%. It has been estimated that 1.2% of the patients 
with an abnormal Papanicolaou test have cervical carcinoma.13,14
Studies have shown that the efficacy of cervical cytological tests dur-
ing the gestational period is the same as during non-gestational periods, 
and such procedures are recommended without restrictions as a screen-
ing method for lesions of the uterine cervix during pregnancy.15 How-
ever, it is extremely important that the physician performing the cyto-
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logical tests should inform the cytologist that this material was collected 
from a pregnant woman, because of the physiological changes in cervi-
cal cytology that occur during pregnancy (hyperplasia of the glandular 
epithelium, presence of decidual cells and Arias-Stella reaction). If not 
informed, less experienced cytopathologists may interpret these changes 
as indicating intraepithelial lesions.9,14,16,17
Another important event is eversion of the endocervical epitheli-
um, which causes the transformation zone to be more exposed to physi-
cal trauma (sexual intercourse), infections or vaginal pH trauma. All of 
these elements generate reparative reactions (immature metaplasia) that 
may be confused with cell atypia of the glandular epithelium and may 
increase the rate of diagnosing preneoplastic lesions of the cervix. In ex-
perienced laboratories, the incidence of these changes is similar for preg-
nant and non-pregnant women, about 0.6%.14,16
Colposcopy
Any pregnant woman with abnormal cytological test results should 
be referred for colposcopy. This, in addition to identifying suspected 
neoplastic lesions, indicates the most appropriate site for a biopsy. This 
procedure makes it possible to rule out or confirm the presence of strom-
al microinvasion or invasion, thereby defining the type of treatment and 
the time when it should be applied, i.e. before or after delivery.9
During pregnancy, the fundamental characteristics of the colpo-
scopic examination do not differ from those among non-pregnant 
women. Examinations with unsatisfactory results are uncommon, 
since the squamocolumnar junction is visible in 90 to 100% of all 
pregnant women.18 The professional responsible for the colposcop-
ic examination should be experienced in examining pregnant wom-
en, because the increased cervical volume, stromal edema and hyper-
plasia of the glandular epithelium give rise to greater mucus produc-
tion, and the decidual reaction may impair accomplishment of the 
examination.13,19 A vaginal speculum examination or evaluation of the 
cervix by quadrants may be necessary. It is also important to point out 
that the increased vascularization of the uterine cervix and the promi-
nent reaction of the metaplastic epithelium to acetic acid may lead to 
a suspicion of a more severe lesion that is confirmed by histopatho-
logical examination.9 Thus, inspection of the cervix and colposcopy 
alone are insufficient to distinguish premalignant lesions from inva-
sive lesions, whereas a biopsy directed by colposcopy is the most sen-
sitive method.9,17,19,20
Biopsy
Among pregnant women, the sensitivity and specificity of directed 
biopsies, in relation to the final diagnosis of the lesion, are 83.7% and 
95.9%, respectively. When cervical biopsies are obtained during preg-
nancy, the risk of bleeding requiring greater accuracy of control is only 
1 to 3%. Occurrences of other complications such as preterm labor and 
chorionic amniorrhexis are rare.17,19
Conization is reserved for pregnant women with suspected inva-
sion, since this diagnosis changes the management to be followed dur-
ing pregnancy in cases in which cytological tests reveal a high-grade le-
sion and colposcopy is unsatisfactory. However, in most cases, coniza-
tion is postponed to the postpartum period.7,20-23 Since most of the le-
sions in pregnant women are located in the ectocervix, undertaking a 
short cone is more appropriate since this procedure is not indicated as a 
treatment but, rather, as a diagnostic method, because of the high rates 
of maternal and fetal complications. In addition, a high incidence of re-
sidual disease is observed in about half the cases.12
The most frequent complications from conization during pregnancy 
are hemorrhage (5% in the first and second trimesters and 10% in the 
third), abortion (25%), preterm labor (12%) and infection (2%). The 
risks of abortion and bleeding are considerably reduced when coniza-
tion is performed during the second trimester, preferentially between 
the 14th and 20th weeks.12,13,21
A study on 26 pregnant women for whom there was discordance 
regarding the presence of an invasive lesion between the biopsy and 
colposcopy showed that the use of CO2 laser conization after the 18
th 
week of pregnancy was not associated with maternal or neonatal com-
plications. All deliveries occurred at term and most of them were via 
the vaginal route. In addition, it was reported that 92.3% of the pa-
tients did not present recurrence of the lesion, after 18 months of fol-
low-up.24 More studies on the use of CO2 laser during pregnancy are 
needed, although this seems to be a less risky technique for both the 
patient and the fetus. However, the duration of the surgery is known 
to be longer when the procedure is performed with a CO2 laser, com-
pared with a high-frequency device. Although the results have been 
satisfactory, vaporization with CO2 cannot be taken to be the man-
agement of choice in these cases, but only as an additional therapeu-
tic option.
Endocervical curettage is contraindicated during pregnancy be-
cause of the risk of premature rupture of the membranes and preterm 
delivery.9,10
Imaging examinations
In general, the doses of radiation involved in imaging diagnostic 
procedures are much lower than the threshold for adverse effects and are 
not associated with fetal death, malformations or mental retardation,25 
which may occur when the absorbed dose is higher than 10 or 15 cGy.4 
The dose to the fetus resulting from standard examinations is lower than 
0.01 Gy or, if expressed as cGy, it is equal to 1 cGy.26 For tomography 
of the abdomen or pelvis, the dose is 920 mGy or 650 mGy, respec-
tively.27 
However, since much relevant information can be obtained using 
other imaging methods, efforts are made to avoid radiography and to-
mography during pregnancy. Although abdominal and pelvic ultra-
sonography and magnetic resonance are not part of the Internation-
al Federation of Gynecology and Obstetrics (FIGO) staging, these are 
considered to be the methods of choice for staging of pregnant women. 
Ultrasound can be used to evaluate kidneys and ureters, while magnetic 
resonance is used to assess tumor size and expansion to adjacent organs 
(parametrium, vagina, bladder and rectum), and for detection of lymph 
node metastases.4,9,28
Since no definitive conclusions regarding deleterious effects in fe-
tuses or embryos exposed to magnetic resonance have been reached, the 
use of this technique is not recommended during the first trimester of 
pregnancy.9,29
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TREATMENT
Precursor lesions of cervical cancer should be monitored during 
pregnancy using cytology and colposcopy performed at three to six-
month intervals. The patients should be reevaluated between six and 
eight weeks after delivery using the same methods, i.e. cytology and col-
poscopy, with a biopsy in cases requiring immediate treatment. A new 
biopsy during gestation is indicated only when there is cytological and 
colposcopic suspicion of progression to invasive disease.7,10-13,17,20-22,30-32 
Studies involving monitoring and observation of patients with in-
traepithelial lesions have shown that these procedures form a safe op-
tion, such that only a very low percentage of cases progress to more se-
vere lesions. Low-grade lesions regress in 48 to 62% of cases, while in 
29 to 38% of cases they remain unchanged.13,22,33 Progression to more 
severe lesions is infrequent: no cases were observed in one series and a 
6% rate was observed in another.13,33 
For high-grade lesions, the percentages are different because the re-
gression rate is lower, ranging from 27.4 to 34.2%, while progression 
of the lesion occurs in 2.7 to 9.7% of the cases. Moreover, 40.3% to 
63.1% of the patients reevaluated after delivery show persistence of the 
lesion.22,30 Thus, expectant management followed by postpartum evalu-
ation is the procedure most indicated for in situ carcinoma diagnosed 
during pregnancy, even though there is a small risk of worsening of the 
lesions.  
INVASIVE CERVICAL CARCINOMA
Pregnancy and cervical carcinoma occurring concomitantly causes 
therapeutic and ethical dilemmas. The management for this situation 
will depend on the gestational age at the time of diagnosis, disease 
staging, size of the lesion and the patient’s wish to maintain pregnan-
cy and fertility, although the possibility of the use of in vitro fertiliza-
tion exists.9
The use of steroids during pregnancy and artificial surfactants for 
neonates has drastically improved the prognosis for preterm newborn 
infants. With these procedures, neonatal intensive care units have start-
ed to have significant success with most neonates born after 24 weeks 
of gestation. This, taken together with the increasing number of studies 
suggesting that postponement of treatment of cervical cancer in preg-
nant women is a safe approach, has led to the use of greater caution re-
garding the time of delivery.10
Among the maternal and neonatal results for pregnant women with 
cervical carcinoma, one study observed that their chance of requiring 
delivery by cesarean section was twice as high and their chance of re-
quiring blood transfusion was nine times as high as among those with-
out cancer. Nevertheless, their risk of postpartum death was no greater. 
The neonates had twice the chance of being premature and seven times 
the chance of neonatal death. In addition, both the patients and new-
borns required prolonged hospital stay, thus involving higher costs for 
the healthcare system.34
During pregnancy, the histopathological type of cervical carcinoma 
is most frequently the squamous cell type (responsible for 80% of the 
lesions), followed by adenocarcinoma. These proportions are similar to 
those observed among non-pregnant women. According to FIGO, the 
stage distribution at the time of diagnosis shows that 70 to 80% of preg-
nant women with cervical cancer are in stage I, 11 to 20% in stage II, 3 
to 8% in stage III and 0 to 3% in stage IV.1,35,36  
Microinvasive carcinoma (stage IA1)
There is no consensus regarding the treatment for microinvasive cer-
vical carcinoma during pregnancy. Some authors have recommended 
conization only if the initial biopsy shows microinvasion, in order to 
rule out the diagnosis of clearly invasive carcinoma. When a microinva-
sive tumor is diagnosed, the approach consists of observation, with col-
poscopy at two-month intervals during the prenatal period and reevalu-
ation six weeks after delivery using cytology and colposcopy, with a new 
biopsy in cases requiring immediate treatment.37 If the diagnosis is made 
after the 24th week, the best approach would be to wait for fetal pulmo-
nary maturity because of the risks of bleeding and preterm labor.9,22 If 
the surgical margins after conization are tumor-free, the patient is con-
sidered to have been cured, but should still undergo colposcopy at two-
month intervals during the prenatal period and reevaluation using cytol-
ogy, colposcopy and possibly biopsy six to eight weeks after delivery.5,9
However, other investigators have suggested that the best approach 
for microinvasive carcinoma diagnosed during pregnancy would be ob-
servation (without conization), with colposcopy at one or two-month 
intervals during prenatal care and reevaluation six weeks after delivery 
using cytology and colposcopy, with biopsy in cases requiring immedi-
ate treatment.2,10
Invasive carcinoma (stages IA2, IB and IIA)
There is no evidence that pregnancy accelerates the natural history 
of cervical cancer. In addition, disease-specific survival is independent 
of the trimester of pregnancy during which the diagnosis is made. There 
is evidence supporting immediate patient treatment if the diagnosis is 
made before the 16th week of pregnancy. If the diagnosis is made after 
this period, the patients with early stage tumors (IA, IB and IIA) can 
wait for fetal pulmonary maturity before starting treatment.38,39
There is wide divergence regarding the gestational age that should 
be considered as the limit for taking an observational approach instead 
of administering immediate treatment, ranging from the end of the first 
trimester to the 20th week.6,39 However, the evidence shows that post-
ponement of treatment may extend for long periods of time. All studies 
reporting the result from postponement of treatment after the 16th week 
of pregnancy, in order to obtain fetal maturity, have shown that the ma-
ternal prognosis was not affected.1,2,9 These studies included approxi-
mately 80 cases in which treatment was postponed for periods ranging 
from one to 40 weeks. The recurrence rate was 5%, i.e. similar to that 
obtained among non-pregnant women.1-4,6,38,39
However, it is of fundamental importance to explain to the mother 
what the potential risks of treatment are and what options are available, 
which always include the immediate termination of pregnancy.
Pregnancy of less than 20 weeks
In these cases, the choice is immediate and definitive treatment by 
means of radical hysterectomy with the fetus in situ40 and lymphadenec-
Diagnosis and treatment of cervical cancer during pregnancy 
Sao Paulo Med J. 2009; 127(6):359-65 363
tomy, or external radiotherapy with the fetus in situ, which in most cases 
will lead to spontaneous abortion. If this does not occur, it will be nec-
essary to empty the uterine cavity before performing complementary 
brachytherapy.2,4,9,10,35 In young patients, radical surgery is the treatment 
of choice, which makes it possible to maintain functioning ovaries and 
to evaluate the real extent of the disease towards the parametria and gan-
glia. Although surgery is associated with morbidity such as bladder dys-
function and infections, these can be quickly resolved. Radiotherapy is 
associated with long-term complications that may even arise as much as 
five years after treatment.39 Among the most frequent complications are 
vaginal fibrosis, cystitis and enteritis.
Some investigators have suggested that postponement of treatment 
until the occurrence of fetal pulmonary maturity can be considered to 
be a second choice for patients with more than 12 weeks of gestation at 
the time of diagnosis.4,9-11,35,36
Pregnancy of more than 20 weeks
Most studies suggest emptying of the uterine cavity by cesarean sec-
tion followed by radical hysterectomy with lymphadenectomy. Neoad-
juvant chemotherapy based on cisplatin can be applied in cases of lo-
cally advanced disease, followed by surgery.2,4,5,10,41
When a diagnosis is made after the 25th week of gestation, the ap-
proach of choice is to wait for fetal pulmonary maturity before perform-
ing a cesarean section, followed by radical hysterectomy with lymph-
adenectomy, or chemotherapy plus radiotherapy.2,4,10 In patients with 
term gestation, the treatment is immediate.5,9,10,35
Despite the larger uterine volume, the results relating to factors such 
as radical hysterectomy, dissection of the parametria, ureteral mobili-
zation and blood loss do not differ significantly from those observed 
among non-pregnant women.5
Some studies have suggested that chemotherapy should be used 
during the second trimester of pregnancy in order to make it possible 
to wait for fetal pulmonary maturity, with definitive treatment applied 
after delivery.25,42-45
Caluwaerts et al. reported the case of a woman in the 17th week of 
pregnancy with a diagnosis of stage IB1 cervical carcinoma who was 
treated with cisplatin (six cycles of 75 mg/m2 for 10 days). She then un-
derwent cesarean section followed by radical hysterectomy and lymph-
adenectomy at 32 weeks of gestation, without adjuvant therapy. After a 
follow-up of 10 months, the patient did not present recurrence of the 
disease.43
In 2007, Bader et al. reported the use of four cycles of cisplatin (50 
mg/m2) and vincristine (1 mg/m2) for 21 days, for a woman in the 19th 
week of pregnancy presenting stage IIA invasive cervical carcinoma. The 
patient underwent cesarean section at 33 weeks of pregnancy, with radi-
cal hysterectomy and lymphadenectomy. Since the patient had lymph 
nodes with metastases, she underwent three cycles of cisplatin (50 mg/
m2), vincristine (1 mg/m2) and bleomycin (25 mg/m2) for 10 days. The 
patient was followed up for 80 months and did not present recurrence 
of the disease.44
Also in 2007, a report was published on the use of cisplatin starting 
during the 24th week of gestation, among patients with stage IB2 cer-
vical carcinoma. Cesarean section was performed during the 33rd week, 
plus radical hysterectomy with pelvic and para-aortic lymphadenectomy 
and ovarian transposition, followed by pelvic radiotherapy and a new 
cisplatin cycle four weeks after surgery.28
The use of chemotherapy for treatment of cervical carcinoma during 
pregnancy seems to be feasible. However, the drugs involved are potent 
teratogens and should be avoided during the first trimester. The main 
fetal effects from administration of therapeutic agents during the sec-
ond and third trimesters relate to low birth weight (observed in 40% of 
the exposed neonates), intrauterine growth restriction, prematurity and 
intrauterine fetal death. Furthermore, chemotherapy should not be per-
formed beyond 35 weeks of gestation, since delivery may occur during 
the period of greatest fetal immunosuppression.4,7,9,24,43-45
Invasive carcinoma (stages IIB, III and IV)
Fortunately, these stages of cervical carcinoma rarely occur during 
pregnancy. The literature suggests that immediate treatment should be 
implemented, consisting of chemotherapy based on the use of cisplatin 
followed by radiotherapy. It has been shown that this combination leads 
to a 12% increase in five-year survival, compared with using radiother-
apy alone.9,37 Regarding diagnoses made during the second trimester of 
gestation, some studies have raised the hypothesis of waiting for fetal 
pulmonary maturity, followed by cesarean section, chemotherapy and 
radiotherapy after delivery. This is the approach of choice in cases diag-
nosed when the fetus is at term.2,5,10
Preservation of fertility
Preservation of fertility in patients with cancer has become an im-
portant part of healthcare because of the growing survival rates after 
treatment and the postponement of maternity, especially among wom-
en from Western countries. The techniques offered for preservation of 
fertility are oocyte cryopreservation, ovary cryopreservation and ova-
ry transposition. Oocyte preservation is an established technique with 
good rates of success, but is limited to women who do not require im-
mediate cancer treatment, since it requires a delay in treatment of up to 
six weeks. For patients who cannot wait for treatment, a more recent 
procedure involves cryopreservation of one or both ovaries, which can 
be transplanted at a later time. Ovary transposition to areas far from the 
site of radiotherapy allows subsequent retrieval of oocytes for in vitro 
fertilization.46-51
DELIVERY ROUTE
Women with a diagnosis of precursor lesions for cervical cancer or 
with cervical carcinoma during the gestational period should be moni-
tored by a multidisciplinary team consisting of an obstetrician, an on-
cogynecologist, a psychologist and nurses experienced with this disease. 
In addition, such patients should be treated at reference centers for both 
cervical cancer and high-risk pregnancies, since delivery should be per-
formed in accordance with the indications of their diagnosis, thus often 
contributing towards the treatment. The importance of concomitant 
presence of a neonatology center with an intensive care unit for these 
neonates should also be emphasized. Since they are often premature, 
with intrauterine growth restriction and consequent low birth weight, 
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these infants born to mothers with a diagnosis of cervical carcinoma 
during pregnancy are at high risk of neonatal death.10,33,52-55
The choice of delivery route is based on the type and grade of the 
lesion. In the presence of precursor lesions for cervical carcinoma, 
whether of low or high grade, vaginal delivery is not contraindicated. 
On the contrary, some authors have correlated spontaneous regression 
of the lesions during the puerperium to the epithelial desquamation 
that occurs during delivery, associated with an improved immunologi-
cal response.10,13,52,53
For cases with microinvasive carcinomas, the vaginal route can 
be chosen when conization with disease-free surgical margins is per-
formed.5 However, other studies have indicated that cesarean section is 
the best approach.9,10
For patients with invasive carcinomas, the delivery route of choice is 
cesarean section. Vaginal delivery may result in the risk of lymphovascu-
lar dissemination of the diseases, excessive bleeding, obstruction of the 
birth canal, laceration of the cervix and implantation of malignant cells 
at the site of episiotomy. In addition, cesarean section enables comple-
mentary surgical treatment of the neoplasia when indicated. During ce-
sarean section, corporal incision in the uterus is preferred. The placenta 
should be extracted and hysterorrhaphy should be performed, followed 
by hysterectomy.4,9,10,53
Few cases of metastasis in the episiotomy after vaginal delivery have 
been reported. The treatment recommended in the literature is surgical 
removal of the lesion followed by radiotherapy.9,10,52
PROGNOSIS
Some studies on precursor lesions for cervical carcinoma diagnosed 
during pregnancy have reported that 10 to 70% regress and disappear 
after delivery, while 25 to 47% persist and 3 to 30% progress. Monitor-
ing during the prenatal period is sufficient until the time for definitive 
treatment after childbirth.11,12,18,20,54 
Studies have shown that pregnant women with invasive cervical car-
cinoma have a better prognosis than non-pregnant women do. On the 
other hand, such findings have been correlated with the larger num-
ber of diagnoses during the early stages of pregnancy. When the cases 
were matched according to staging, the characteristics of the course of 
the disease, survival rates and complications from treatment were the 
same.5,7,10,15
The maternal prognosis does not seem to be affected in cases of a di-
agnosis made after 16 weeks of pregnancy with postponement of treat-
ment in order to wait for fetal pulmonary maturity. The rate of recur-
rence in these cases is similar to that observed among non-pregnant 
women.4,9,11,35,36
The fetal prognosis is influenced by the type of treatment and by the 
choice of time when the treatment should be performed, since neona-
tal morbidity and mortality are related to prematurity.5,10,24,44,55 Even in 
cases of diagnosis during the third trimester, with the option of imme-
diate treatment, the neonates had greater morbidity and mortality than 
among other premature neonates of the same gestational age, since in-
fants born to mothers with cervical carcinoma had lower birth weight 
and higher risk of death on delivery. In addition, the fetal prognosis also 
depends on intrauterine exposure to cytotoxic drugs, thus demonstrat-
ing the importance of adequate prenatal and perinatal care provided by 
a group with experience in such cases, at a high-risk unit.5,9,10,34
CONCLUSION
Pregnancy is an excellent opportunity for detection of preneoplastic 
lesions and tumors in the early stages. All patients with abnormal cyto-
logical test results should be subjected to colposcopy, which will indicate 
whether a biopsy is needed and what site is best for performing it. Col-
poscopy can also rule out or confirm the presence of microinvasion or 
invasion, thereby defining the type of treatment and the delivery timing 
and route. Conization in pregnant women is reserved for patients with 
suspected invasion and is associated with high rates of complications.
Precursor lesions for cervical carcinoma and in situ carcinoma 
should be monitored during pregnancy and reevaluated after delivery, 
which may be done vaginally.
For microinvasive carcinoma, there are no reports in the literature re-
garding the best approach or the time for treatment and type of delivery. 
When the lesion is diagnosed up to the 14th week of pregnancy, coniza-
tion seems to be the best procedure. After this time, delivery should be 
awaited. This could be via the vaginal route if the conization margins are 
disease-free. If conization has not been performed or if the margins are 
involved, cesarean section should be the choice for delivery route.
In cases of invasive carcinoma detected up to the 12th week of preg-
nancy, patient treatment is the priority. When a diagnosis is made in the 
second trimester, it is possible to wait until fetal pulmonary maturity. 
Many recent studies have indicated the use of chemotherapy in order to 
stabilize the disease until the time of delivery, which should preferen-
tially be by cesarean section.
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